20-F: Adagene Narrows 2025 Net Loss, Boosted by Strategic Collaborations

Adagene Inc. reported a significantly reduced net loss of $17.6 million in 2025, driven by increased licensing and collaboration revenue and focused R&D efforts on its lead candidate, ADG126.

Summary

• Net loss for the year ended December 31, 2025, decreased by 47.3% to $17.6 million, compared to $33.4 million in 2024.
• Licensing and collaboration revenue significantly increased to $7.7 million in 2025 from $0.1 million in 2024, primarily due to agreements with Sanofi, ConjugateBio, and Third Arc Bio.
• Research and development expenses decreased by 23.4% to $22.0 million in 2025, down from $28.8 million in 2024, reflecting prioritization of the ADG126 program.
• Administrative expenses decreased by 2.7% to $7.1 million in 2025, compared to $7.3 million in 2024, due to cost-control measures.
• Cash and cash equivalents stood at $74.5 million as of December 31, 2025.
• ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in Phase 1b/2 and Phase 2 clinical development, focusing on metastatic MSS colorectal cancer (CRC).
• ADG126 received FDA Fast Track designation in combination with pembrolizumab for adult patients with metastatic MSS CRC without current or active liver metastases.
• Clinical data for ADG126 in combination with pembrolizumab in MSS CRC patients showed an overall response rate (ORR) of 17% in the 10 mg/kg Q3W cohort and 29% in the 20 mg/kg cohorts (loading dose + maintenance).
• Median overall survival (OS) for the 10 mg/kg cohorts was 19.4 months, comparing favorably with current standard of care treatments and historical benchmarks.
• ADG206, a masked, Fc-enhanced anti-CD137 agonistic POWERbody, completed Phase 1 development with a favorable safety profile.
• ADG106, an anti-CD137 NEObody, was deprioritized to optimize resources for other programs.
• New preclinical programs include ADG138 (HER2xCD3 POWERbody bispecific TCE), ADG152 (CD20xCD3 POWERbody), ADG153 (masked anti-CD47 IgG1 SAFEbody), and CD28 T-cell engagers.
• A strategic investment of up to $25.0 million from Sanofi B.V. was initiated in July 2025, with a first closing of $17.0 million for Series A non-voting contingently redeemable convertible preferred shares.
• The company issued 1,000,000 warrants to a consultant in July and September 2025 as compensation for investor relations and business development services.
• The company continues to rely on third-party manufacturers (WuXi Biologics) and CROs for its R&D and manufacturing needs.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing. The significant reduction in net loss, substantial increase in collaboration revenue, and positive clinical progress for ADG126, including FDA Fast Track designation, are strong indicators of operational and strategic advancement. However, the company remains in a net loss position, relies on future financing, and faces inherent risks of early-stage biotech development and geopolitical factors.

Positives

• Net loss significantly decreased by 47.3% in 2025 to $17.6 million, indicating improved financial efficiency or increased revenue streams.
• Licensing and collaboration revenue saw a substantial increase to $7.7 million in 2025, reflecting successful new partnerships and option exercises.
• R&D expenses decreased by 23.4% to $22.0 million, suggesting focused resource allocation and prioritization of key pipeline assets.
• ADG126 received FDA Fast Track designation, which could expedite its development and review process for metastatic MSS CRC.
• Clinical data for ADG126 in MSS CRC patients showed encouraging efficacy, with ORRs of 17% (10 mg/kg Q3W) and 29% (20 mg/kg cohorts), and a median OS of 19.4 months for 10 mg/kg cohorts, comparing favorably to standard of care.
• ADG126 demonstrated a manageable safety profile, with no dose-limiting toxicity or Grade 4/5 treatment-related adverse events (TRAEs) in the 10 mg/kg and 20 mg/kg cohorts.
• The company expanded its collaboration with Sanofi, which exercised an option for a third SAFEbody discovery program, validating the technology.
• A new partnership with Third Arc Bio for two masked CD3 T cell engagers includes an upfront payment of $5 million and potential milestones up to $840 million, plus royalties.
• Collaboration with ConjugateBio on bispecific ADCs further demonstrates scalable platform potential and generates upfront payment and potential milestones/royalties.
• ADG206 completed Phase 1 with a favorable safety profile, and preclinical data showed 4-fold stronger anti-CD137 agonistic activity than a benchmark antibody.
• ADG153, a masked anti-CD47 IgG1 SAFEbody, showed strong ADCC/ADCP activity without serious safety liabilities and reduced anemia-related issues in preclinical studies, making it IND-ready.
• The company's internal control over financial reporting was effective as of December 31, 2025.

Negatives

• The company continues to incur significant net losses, with an accumulated deficit of $328.8 million as of December 31, 2025.
• Cash and cash equivalents decreased to $74.5 million in 2025 from $85.2 million in 2024, indicating continued cash burn from operations.
• ADG106, an anti-CD137 NEObody, was deprioritized, leading to termination of its clinical trials, representing a setback for that specific program.
• The company has a limited operating history and no products approved for commercial sale, relying heavily on future product approvals and collaborations for revenue generation.
• The company will need substantial additional financing to fund its growth and operations, which may not be available on acceptable terms or at all, potentially leading to dilution of existing shareholders.
• The company was likely a passive foreign investment company (PFIC) for 2025 and faces a significant risk of being a PFIC for 2026 and subsequent years, which could lead to adverse U.S. federal income tax consequences for U.S. investors.
• The company relies on a single primary contract manufacturer (WuXi Biologics) for certain biologic drug substances, posing a supply chain risk if restrictions or prohibitions are imposed on this supplier (e.g., due to the BIOSECURE Act).

Risks

• Uncertainties with the PRC legal system, including sudden changes in policies, laws, and regulations, could adversely affect operations.
• The PRC government has significant oversight and discretion over business conduct, which may influence operations at any time.
• ADSs may be prohibited from trading in the United States under the HFCAA if the PCAOB is unable to inspect or investigate auditors located in China for two consecutive years, potentially leading to delisting.
• The Accelerating Holding Foreign Companies Accountable Act reduces the non-inspection period from three years to two, increasing delisting risk.
• Restrictions on transferring scientific data abroad due to PRC regulations (e.g., Scientific Data Measures, Data Security Law, Cybersecurity Review Measures) could hinder R&D.
• Failure to comply with existing or future laws and regulations related to privacy or data security could lead to government enforcement actions, fines, private litigation, and adverse publicity.
• Dividends from PRC subsidiaries may be taxed at a higher rate if the Hong Kong subsidiary is deemed to benefit from a tax-driven structure.
• Difficulties in effecting service of legal process, enforcing foreign judgments, or bringing actions in China against the company or management based on foreign laws.
• Recent litigation and negative publicity surrounding China-based companies listed in the U.S. may increase regulatory scrutiny and negatively impact ADS trading price.
• Changes in U.S. and international trade policies, particularly with regard to China, including potential restrictions on working with certain Chinese biotechnology companies (e.g., BIOSECURE Act), may adversely impact business and supply chain.
• Requirement to obtain approval or complete filing with the CSRC or other PRC government authorities for overseas securities issuances or maintaining listing status, with uncertainties regarding approval timelines and outcomes.
• Classification as a PRC resident enterprise for tax purposes could result in unfavorable tax consequences for the company and non-PRC shareholders.
• The biopharmaceutical industry in China is highly regulated, and changes in regulations may affect approval and commercialization of product candidates.
• Substantial uncertainties exist with respect to the interpretation and implementation of the Foreign Investment Law.
• Potential obligations to make additional social insurance and housing fund contributions in China.
• Lease agreements for leased properties in China have not been registered, potentially exposing the company to fines.
• Failure to comply with PRC regulations regarding registration requirements for employee stock incentive plans may subject participants or the company to fines.
• Uncertainty with respect to indirect transfers of equity interests in PRC resident enterprises by non-PRC holding companies, potentially leading to tax liabilities.
• Revocation or challenge of preferential tax treatments by PRC tax authorities.
• PRC regulations on loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent the use of IPO proceeds.
• Reliance on dividends and other distributions from PRC subsidiaries, which may be limited by PRC laws and foreign exchange controls.
• Fluctuations in exchange rates could have a material adverse effect on results of operations and ADS value.
• Limited operating history makes it difficult to evaluate current business and predict future performance.
• Incurrence of net losses historically and expectation to continue incurring losses in the near future.
• Need for substantial additional financing, which may not be available on acceptable terms or at all, leading to dilution or relinquishing rights.
• Certain shareholders have board representation rights, and their interests may differ from other shareholders.
• Inability to identify or discover new product candidates, or misallocation of limited resources to less profitable candidates.
• Failures or setbacks in proprietary platforms (DPL, NEObody, SAFEbody, POWERbody) could negatively affect business.
• Product candidates may face competition sooner than anticipated from biosimilar or other biologic products.
• Substantial dependence on the success of lead product candidate ADG126 and ability to advance other candidates; clinical trials may not be successful.
• Clinical trials are expensive, time-consuming, difficult to design and implement, and may fail to demonstrate adequate safety and efficacy.
• Delays in ongoing clinical trials due to various factors, including regulatory authorization, IRB approval, patient enrollment, safety concerns, or third-party performance.
• Interim, topline, or preliminary data from clinical trials may change as more patient data become available and are subject to audit and verification.
• Lengthy, time-consuming, and unpredictable regulatory approval processes (FDA, NMPA, etc.) for product candidates.
• Disruptions at the FDA and other government agencies due to funding shortages or global health concerns could hinder approvals.
• Inability to obtain approval or commercialize products outside the United States, limiting full market potential.
• FDA, NMPA, and similar foreign regulatory authorities may not accept data from trials conducted outside their jurisdictions.
• Product candidates may cause undesirable adverse events or side effects, delaying or preventing regulatory approval or leading to negative consequences post-approval.
• Unsuccessful attempts to obtain Orphan Drug Designation for product candidates.
• Inability to obtain accelerated approval through expedited pathways, requiring additional costly studies.
• Ongoing regulatory obligations and reviews post-approval, potentially leading to significant additional expense or penalties for non-compliance.
• Significant competition and rapid technological changes in the biotechnology and pharmaceutical industries.
• Lack of in-house manufacturing, sales, marketing, or distribution capabilities, requiring reliance on third parties.
• Coverage and reimbursement limitations or unfavorable pricing regulations for product candidates could harm business.
• Exposure to specific risks of conducting business in international markets due to global operations.
• Difficulties in managing organizational growth and expanding employee base.
• Disruptions in financial markets and economic conditions affecting capital raising ability.
• Allegations of non-compliance with laws and sanctions could harm reputation, revenues, and liquidity.
• Potential future acquisitions or strategic collaborations may increase capital requirements, dilute shareholders, or incur debt/contingent liabilities.
• Exposure to liabilities under the U.S. Foreign Corrupt Practices Act and Chinese anti-corruption laws.
• Failure to comply with applicable regulations and industry standards or obtain various licenses and permits.
• Failure to comply with environmental, fire protection, drainage, or health and safety laws and regulations, leading to fines or penalties.
• Security breaches, loss of data, and other disruptions compromising sensitive information and exposing the company to liability.
• Inability to protect intellectual property rights throughout the world, including challenges to patents, trade secrets, and trademarks.
• Changes in patent law diminishing the value of patents.
• Patent terms may not be sufficient to effectively protect product candidates.
• Uncertainty of the length of patent term extensions and data/market exclusivities, increasing generic competition risk.
• Failure to enter into invention assignment and confidentiality agreements with all employees and third parties, or such agreements not preventing ownership disputes or unauthorized disclosure.
• Claims that employees have wrongfully used or disclosed alleged trade secrets of former employers.
• Claims challenging the inventorship of patents and other intellectual property.

Future Outlook

The company plans to complete enrollment of the randomized Phase 2 dose optimization study for muzastotug (ADG126) in 2026, provide initial clinical data from a new cohort combining muzastotug with pembrolizumab and fruquintinib in MSS CRC, and share results from the Roche collaboration evaluating muzastotug in triplet combination for HCC. Preliminary clinical data, including pathological responses, from an investigator-initiated Phase 2 neoadjuvant trial for muzastotug in colorectal cancer are also expected. The company also aims to establish additional collaboration/licensing agreements.

Management Comments

• We believe the well-tolerated safety profile of our masked anti-CTLA-4 SAFEbody ADG126 enables continuous dosing in combination with anti-PD-1 to drive the efficacy in patients with cold tumors such as MSS CRC, and in patients with PD-L1 low expressing or PD-1 resistant warm tumors.
• The totality of data to date supports that ADG126 plus pembrolizumab has potential to be a best-in-class treatment for patients with MSS CRC.
• We believe our proprietary antibody discovery and engineering DPL platform significantly increases R&D productivity for antibody drug discovery.
• We believe that the high-affinity and cross-reactive primary hits from our DPL screening save time and cost from discovery to early clinical proof of concept.

Industry Context

StockSavvy.ai notes that Adagene Inc. operates in the highly competitive and rapidly evolving biopharmaceutical industry, particularly in cancer immunotherapies. The company's focus on next-generation anti-CTLA-4 therapies, like ADG126, addresses a critical need to overcome the dose-dependent toxicities seen with existing agents such as ipilimumab and tremelimumab, which have limited their broader clinical acceptance. The strategic collaborations with major pharmaceutical companies like Sanofi and Exelixis, and the use of advanced platforms (NEObody, SAFEbody, POWERbody), align with industry trends towards precision medicine, combination therapies, and leveraging computational biology for drug discovery. The deprioritization of ADG106 reflects the industry's need for focused resource allocation in a capital-intensive sector. The company's efforts to develop masked T-cell engagers and anti-CD47 therapies also position it within high-growth areas of oncology, where safety and efficacy challenges are significant.

Comparison to Industry Standards

• ADG126's combination safety profile with pembrolizumab is comparable to pembrolizumab alone, and its rate of Grade 3 and higher TRAEs is much lower than historically reported with currently approved standard of care anti-CTLA-4 combinations (e.g., nivolumab and ipilimumab), suggesting a potential best-in-class safety profile.
• Preclinical data for ADG206 demonstrated 4-fold stronger anti-CD137 agonistic activity of its activated form compared to a benchmark antibody (urelumab analog), indicating superior potency.
• ADG153, an anti-CD47 IgG1 SAFEbody, showed significantly reduced anemia-related and antigen sink liabilities compared to a benchmark IgG4 antibody (magrolimab analog), with only an 8% decrease in red blood cell counts versus 49% for the benchmark, suggesting a superior safety profile for anti-CD47 therapy.
• ADG138, a novel HER2xCD3 POWERbody, demonstrated a 100-fold greater reduction in cytokine release compared to its parental non-masked TCE, addressing a major safety concern for T-cell engagers and showing an impressively high therapeutic index relative to a benchmark antibody (DS-8201).

Management Changes

Corporate Governance

Legal Proceedings

• As of the date of this annual report, the company is not presently a party to any legal proceedings that, if determined adversely, would individually or taken together have a material adverse effect on its business, results of operations, financial condition or cash flows.

Related Party Transactions

• Received research and development services from WuXi AppTec Group (parent company of a principal shareholder) totaling US$0.1 million in 2025, with US$0.2 million due as of December 31, 2025.
• Received research and development services, including manufacturing and quality control testing, from WuXi Biologics (Cayman) Inc. (controlled by the ultimate controlling party of a principal shareholder) totaling US$1.5 million in 2025, with US$10.1 million due as of December 31, 2025.

Stakeholder Impact

• Shareholders: Potential for dilution from future capital raises, but also potential for value appreciation from pipeline progress and successful collaborations. U.S. shareholders face potential adverse tax consequences if the company is deemed a PFIC.
• Employees: Continued share-based compensation plans aim to attract and retain qualified personnel. Changes in R&D focus led to deprioritization of ADG106, potentially impacting associated personnel.
• Customers/Partners: Existing and new collaboration agreements (Sanofi, Exelixis, Third Arc Bio, ConjugateBio, Roche, Merck) indicate strong partnerships and potential for new therapeutic options.
• Creditors: The company's ability to service debt depends on future profitability and cash flow, which are currently negative, but mitigated by existing cash and new financing.
• Regulatory Authorities: Ongoing compliance with FDA, NMPA, and other international regulations is critical for product development and commercialization, with non-compliance posing significant risks.

Next Steps

• Complete enrollment of the ongoing randomized Phase 2 dose optimization study for muzastotug (ADG126).
• Provide initial clinical data from a new cohort of patients in the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in combination with standard of care (fruquintinib) in MSS CRC patients.
• Share results of the clinical trial collaboration with Roche, evaluating muzastotug in triplet combination with atezolizumab and bevacizumab in first-line treatment of locally advanced or metastatic hepatocellular carcinoma (HCC).
• Provide preliminary clinical data, including pathological responses, from investigator-initiated Phase 2 trial for neoadjuvant muzastotug + pembrolizumab in colorectal cancer.
• Establish additional collaboration/licensing agreements.

Key Dates

Recommendation

Adagene Inc. demonstrates significant progress in its clinical pipeline, particularly with ADG126 showing promising efficacy and a favorable safety profile in MSS CRC, leading to FDA Fast Track designation. The substantial increase in licensing and collaboration revenue in 2025, coupled with new strategic partnerships, validates its technology platforms and provides crucial funding. However, the company continues to incur net losses and will require additional financing, posing dilution risks. The potential PFIC status for U.S. investors and geopolitical risks related to China add layers of uncertainty. While the clinical advancements and strategic collaborations are positive, the early-stage nature of its pipeline and ongoing financial needs warrant a 'hold' recommendation, suggesting investors monitor further clinical trial results and financial stability before making new investment decisions.

Keywords

Biotechnology, Immunotherapy, Cancer, Antibody therapeutics, ADG126, CTLA-4, SAFEbody, NEObody, POWERbody, Clinical trials, Oncology, Colorectal cancer, MSS CRC, Pembrolizumab, KEYTRUDA, Sanofi, Exelixis, Third Arc Bio, ConjugateBio, Drug development, SEC filing, 20-F, Biologics, CD137, CD3 T cell engagers, CD47, HER2, CD20, Preclinical, Regulatory approval, FDA Fast Track, China, PRC, Intellectual property, Financial results